Multiple pathways such as nuclear factor-κB (NF-κB), JAK/STAT3, PI3K/AKT have been activated under therapeutic pressure in breast cancer and non-small cell lung cancer (Mao et al., 2015; Shien et al., 2017). This evidence concerns the gene NFKB1 and breast cancer.